Epia Neuro Launches with a BCI device for Stroke Recovery
Advertisement
The platform integrates a minimally invasive BCI with assistive devices and AI-driven support to help stroke survivors translate neural signals into functional movement
San Francisco-based medtech startup Epia Neuro has announced its official launch aimed at restoring function in patients affected by stroke and addressing cognitive decline.
The medtech startup, which focuses on developing intent-driven neural technology, is advancing its proprietary brain-computer interface (BCI) platform designed to translate neural signals into actionable outputs.
The platform integrates a minimally invasive, long-lifetime “read/write” brain-computer interface (BCI) with assistive devices and AI-driven support to help stroke survivors translate neural signals into functional movement and daily independence.
The device is designed for surgical scalability and long-term durability and can be implanted within the skull in under an hour through a minimally invasive procedure.
Additionally, the implanted system is completely discreet and externally invisible, charged through a non-invasive headset, and designed for long lifetime use with the ability to be replaced or upgraded.
Further, the platform is being trained to interpret user intent in real-time by combining Neural signals with contextual data from external sensors to predict and drive assistive actions.
This approach is expected to enable the system to predict and control actions such as upper-limb grip movement through a motor prosthetics device for easy access and use.
Furthermore, the platform incorporates both sensing and stimulation capabilities at both the cortex and deep in the brain, enabling interactions with neural pathways and supporting potential use alongside cortical and deep brain stimulation approaches where clinically appropriate.
Reportedly, the company is planning first-in-human demonstrations of its system later in 2026 at the Department of Neurosurgery at Lenox Hill Hospital in New York, marking an early step toward clinical validation.
The initial focus of the company is on stroke rehabilitation, seeking to help patients regain motor function by reinforcing neural pathways and enabling more effective recovery.
The company further plans to expand its footprint beyond stroke to address cognitive decline and other neurological disorders, focusing on long-term solutions for the growing ageing population.
Commenting on the new launch, Michel Maharbiz, Chief Executive Officer, Epia Neuro, said, “Epia Neuro was founded to restore meaningful function, provide real independence, and ultimately provide the support individuals need to be fully present in their lives. Over the past five years, our team has been building our first product: a system that interprets neural intent in real time and translates it into rehabilitation therapies and practical, everyday assistance. We’re starting with stroke and plan to rapidly expand into additional neurological conditions.”
Stay tuned for more such updates on Digital Health News
